Effects of increased human tumor necrosis factor-like molecule 1A expression in peripheral blood of children with acute Guillain-Barre syndrome on interferon-gamma secretion

BACKGROUND： Human tumor necrosis factor-like molecule 1A （hTL1A） is a strong T helper cell type 1 （Thl） co-stimulator. Guillain-Barre syndrome （GBS） is an autoimmune disorder of the nervous system, which is mediated by Thl cells. OBJECTIVE： To determine hTL1A expression in peripheral blood T lymphocytes of acute GBS children and the effects of hTL1A on secretion of interferon-γ. DESIGN, TIME AND SETTING： A randomized, controlled, neuroimmunological in vitro study was performed at the Central Laboratory of First Hospital of Jilin University, China from November 2005 to November 2007. MATERIALS： Venous blood samples were obtained from 6 healthy donors, aged 6-12 years （all routine blood examination items were normal）, and 6 additional children with acute GBS, aged 6-12 years. The GBS children fell ill within 1 week and were not treated with hormones or immunoglobulin Purified recombinant human soluble tumor necrosis factor-like molecule 1A （rhsTL1A, 1 mg/mL, relative molecular mass 22 000, 6× His tag, soluble form） was supplied by the Central Laboratory of First Hospital of Jilin University, China. METHODS： Peripheral blood mononuclear cells were isolated from healthy donors using the standard Ficoll gradient centrifugation and were incubated in 96-well culture plates. The cells were assigned to the following groups： control （2 μg/mL phytohemagglutinin）, 2μg/mL phytohemagglutinin ＋ 25, 100 and 400 ng/mL rhsTL1A. T cell proliferation was quantified using the tritiated thymidine （3H-TdR） method. Serum interferon-γ levels in acute GBS children were detected by enzyme-linked immunosorbent assay （ELISA）. The ratio of hTL1A-positive T cells to CD3-positive T cells in peripheral blood of acute GBS children was determined using flow cytometry. Following in vitro pre-activation of peripheral blood mononuclear cells by 2 μg/mL phytohemagglutinin, the peripheral blood mononuclear cells were treated with 400 ng/mL exogenous rhsTLIA. Finally, peripheral blood mononuclear cell-secreted interferon-γlevels were measured by ELISA. MAIN OUTCOME MEASURES： The following parameters were measured： rhsTLIA stimulation index to stimulate proliferation of T cells; the serum interferon-γ levels in acute GBS children; the ratio of hTL1A-positive cells to CD3-positive cells; the levels of interferon-γ secreted by peripheral blood mononuclear cells in acute GBS children, as well as rhsTL1A-stimulated interferon-γ levels. RESULTS： T cell proliferation assay revealed that the stimulation index in each rhsTL1A group was greater than the control group. The stimulation index of the 400 ng/mL rhsTL1A group was the greatest. Serum interferon-γ levels in acute GBS children were significantly greater than the control group （P 〈 0.05）. The ratio of hTLIA＋ CD3＋ T cells to CD3＋ T cells in acute GBS children was significantly greater than the control group （P 〈 0.01 ）. Phytohemagglutinin stimulated peripheral blood mononuclear cells to a greater extent than 400 ng/mL rhsTL1A in the acute GBS group, and the secreted interferon-γ levels were significantly increased （P 〈 0.05）. CONCLUSION： In T cells pre-activated with 2 μg/mL phytohemagglutinin, proliferation was effectively increased with 400 ng/mL rhsTL1A treatment. Expression of hTLIA was increased in activated T cells from peripheral blood of acute GBS children, followed by increased interferon-γ secretion. These mechanisms are considered to be part of the pathological process that induces the secretion of inflammatory cytokines in GBS syndrome.     

Guillain-Barre综合征患儿血清白介素-18、白介素-13水平的变化

目的探讨白介素(IL)-18、IL-13在Guillain-Barre综合征(GBS)患儿血清中的含量变化及意义。方法采用酶联免疫吸附法(ELISA)测定GBS患儿急性期与恢复期血清IL-18、IL-13水平,并与正常对照组比较。结果GBS患儿急性期血清IL-18[(44.87±7.53)pg/ml]与IL-13[(37.46±6.94)pg/ml]水平均明显高于恢复期[和(38.25±5.86)pg/ml、(32.14±6.89)pg/ml]和正常对照组[(32.35±4.93)pg/ml、(24.76±5.59)pg/ml](均P<0.01);且病情重者[(47.02±8.39)pg/ml、(39.46±6.72)]pg/ml]明显高于病情轻者[(41.96±5.58)pg/ml、(34.51±6.25)pg/ml](均P<0.05);GBS患者恢复期血清IL-18、IL-13水平仍高于正常对照组(均P<0.01);相关分析发现GBS病情与血清IL-18、IL-13水平呈正相关(r=0.116,0.078,均P<0.05)。结论GBS患儿血清IL-18、IL-13含量增加,其可能参与了GBS的发病机制。     

新型隐球菌性脑膜炎临床特点分析与脑脊液Th1-Th2细胞因子检测

研究背景新型隐球菌性脑膜炎是新型隐球菌感染脑膜和(或)脑实质引起的中枢神经系统感染性疾病,其发生、发展和转归在一定程度上取决于患者自身免疫功能,尤其与辅助性T细胞亚群Th1/Th2免疫应答失衡有关。本研究旨在探讨新型隐球菌性脑膜炎患者中枢神经系统局部Th1和Th2免疫应答作用。方法采用酶联免疫吸附试验定量检测脑脊液Th1细胞因子[干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)]和Th2细胞因子[白细胞介素-10(IL-10)]水平,并动态监测脑脊液细胞学变化。结果脑膜炎组患者脑脊液Th1细胞因子IFN-γ、TNF-α为(11.17±1.50)和(18.74±2.97)pg/ml,低于对照组的(17.69±2.34)和(28.83±3.55)pg/ml(均P=0.000),Th2细胞因子IL-10为(43.65±10.12)pg/ml,高于对照组的(7.80±1.30)pg/ml(P=0.000);急性期IFN-γ、TNF-α为(11.17±1.50)和(18.74±2.97)pg/ml,低于稳定期的(17.70±2.34)和(22.93±1.53)pg/ml(均P=0.000),IL-10为(43.65±10.12)pg/ml,高于稳定期的(22.93±7.39)pg/ml(P=0.000)。脑膜炎组患者脑脊液IFN-γ/IL-10、TNF-α/IL-10比值低于对照组(均P=0.000),急性期亦低于稳定期(均P=0.000)。结论 Th2免疫应答模式在新型隐球菌性脑膜炎急性期起重要作用,至稳定期转变为以Th1为主的免疫反应。提示Th1/Th2免疫应答失衡与新型隐球菌性脑膜炎发病机制密切相关。     

γ干扰素上调吉兰一巴雷综合征患者外周血中CD4^＋CD25^＋调节性T细胞的研究

目的探讨γ干扰素（IFN-γ）诱导吉兰-巴雷综合征（GBS）患者外周血CD4^＋CD25 T细胞转化为CD4^＋CD25^＋调节性T细胞的可行性。方法不同浓度IFN-γ刺激GBS患者外周血中的CD4^＋CD25T细胞。Real-timePCR检测诱导CD4^＋CD25^＋调节性T细胞中FoxP3的表达,共培养检测其抑制功能;结果与健康人中天然的CD4^＋CD25^＋调节性T细胞比较。结果IFN-γ可诱导CD4^＋CD25^＋T细胞转化为CD4^＋CD25^＋调节性T细胞。IFN-γ40ng.mL^-1诱导的CD4^＋CD25^＋调节性T细胞中FoxP3表达含量最高,但仍然低于天然的CD4^＋CD25^＋调节性T细胞;其抑制能力最强,与天然的CD4^＋CD25^＋调节性T细胞比较差异无统计学意义。结论IFN-γ可诱导GBS患者外周血CD4^＋CD25^＋T细胞转化为CD4^＋CD25^＋调节性T细胞,IFN-γ,40ng.mL^-1诱导的CD4^＋CD25^＋调节性T细胞表型和功能与天然的CD4^＋CD25^＋调节性T细胞相当。     

吉兰-巴雷综合征患者血浆Sema-4A水平与免疫细胞相关性研究

目的检测sema-4A在吉兰-巴雷综合征(Guillain-Barrésyndrome,GBS)患者外周血血浆中及免疫细胞中的表达水平,探讨sema-4A在GBS致病机制中的作用。方法选择作者医院收治的GBS患者18例,另选健康体检者18名作对照,并根据hughes评分将GBS患者划分为轻型与重型。收集GBS患者急性期、恢复期及对照组外周血血浆及单个核细胞,利用ELISA法检测外周血血浆中sema-4A表达水平,比较各组血浆sema-4A表达量变化。通过流式细胞术检测sema-4A在DC细胞、B细胞、CD4~+T细胞等单个核细胞的表达,比较各类单个核细胞表达sema-4A的差异。分析血浆sema-4A表达水平与表达sema-4A的免疫细胞频率及疾病严重程度的相关性。结果 GBS患者急性期血浆sema-4A的表达水平[(0.6162±0.1440)ng/mL]高于恢复期及对照组[分别(0.1071±0.0328)ng/mL、(0.0904±0.0249)ng/mL),均P0.05]。重型GBS患者急性期血浆sema-4A表达水平高于轻型GBS[分别为(0.7351±0.1172)ng/mL、(0.5009±0.0825)ng/mL,t=2.467,P=0.035)]。GBS急性期患者血浆sema-4A表达水平与hughes评分呈正相关(r=0.79,P=0.025)。GBS急性期患者表达sema-4A的DC细胞频率[(3.7260±0.7516)%]及B细胞频率[(2.8072±0.5548)%]高于恢复期[分别为(1.6912±0.4322)%、(1.6039±0.3091)%;均P0.05]及对照组[分别为(1.7194±0.3624)%、(1.5027±0.3208)%;均P0.05]。GBS急性期患者表达sema-4A的DC细胞频率与血浆sema-4A表达水平之间呈正相关(r=0.95,P=0.032)。结论GBS急性期Sema-4A表达增高,并与病情严重程度及DC细胞频率相关。Sema-4A可能是GBS急性期病情严重程度的一个评价指标。     

吉兰-巴雷综合征患者免疫球蛋白治疗前后T淋巴细胞亚群的变化及其意义

目的 研究吉兰-巴雷综合征(GBS)患者应用静脉大剂量注射免疫球蛋白(IVIG)治疗前后T淋巴细胞亚群的变化,并进一步探讨IVIG治疗GBS的可能机制.方法 选择31例临床确诊的GBS患者,以治疗前后作为自身对照,根据治疗效果评定为效优组和效劣组,应用流式细胞分析仪检测GBS患者外周血中T淋巴细胞亚群相对计数.结果 ①GBS患者急性期治疗后CD8+T细胞(28.77%±11.02%)和CD4+CD29+T细胞百分率(56.71%±12.44%)较治疗前(分别为31.84%±12.35%、62.40%±12.72%)显著降低(t=2.995、3.919,P＜0.05),CD4+/CD8+值和CD4+CD45RA+T细胞百分率较治疗前显著升高(t=2.368、3.860,P＜0.05),但治疗前后CD3+T细胞和CD4+T细胞百分率差异无统计学意义.②效优组CD8+T细胞和CD4+CD29+T细胞百分率较治疗前显著降低(t=2.144、3.343,P＜0.05),CD4+/CD8+值和CD4+CD45RA+T细胞百分率较治疗前显著升高(t=2.159、3.277,P＜0.05),效劣组T淋巴细胞亚群分布在治疗前后未发生明显变化.③在本组资料中,IVIG治疗急性期GBS 2周内的显效率为61.29%(19/31),无死亡病例.结论 急性期GBS患者在IVIG治疗前后发生了不同程度T淋巴细胞亚群分布的改变,为探讨GBS的发病机制及IVIG治疗GBS的机制提供了免疫学基础;IVIG治疗效果好,能够有效抑制病情进展,促进神经功能恢复.     

Leptin enhances the release of cytokines by peripheral blood mononuclear cells from acute multiple sclerosis patients

Objective To explore the effect of leptin on cytokine production by PBMCs obtained from MS patients either in acute (relapse) or in stable (nonrelapse) phase of disease. Methods PBMCs were collected from 25 untreated acute MS patients, 11 stable MS patients and 20 healthy controls. PBMCs were cultured either with RPMI-1640 alone or with leptin (1.25 nmol /ml) , phytohemagglutinin (PHA) (100μg/ml) , and leptin PHA. 72 h later the supernate of the culture medium were collected and stored at -70℃. The pro-inflammatory cytokine (IFN-γ) concentration were determined using an enzyme-linked immunosorbent assay (ELISA) , and the anti-inflammatory cytokine (IL-4) concentration were investigated by radioimmunity methods. Results Our data showed that leptin induced IFN-γ production by PBMCs of patients in an acute phase of disease but not in a stable phase or in healthy controls. Moreover, we found that PHA induced IL-4 production by PBMCs of patients in an acute phase of disease, but leptin inhibited this ability of PHA. Conclusiotl Leptin can affect on pro- and anti-inflammatory cytokine production by PBMCs collected from MS patients, may be this connected with leptin increase the susceptiveness of MS.     

实验性自身免疫性重症肌无力大鼠T淋巴细胞IFN-γ-iNOS-NO通路的研究

目的 探讨实验性自身免疫性重症肌无力(EAMG)大鼠T淋巴细胞干扰素-γ(IFN-γ)-诱导型一氧化氮合酶(iNOS)-一氧化氮(NO)通路的表达水平.方法 将大鼠随机分为EAMG组、正常对照组、完全弗氏佐剂(CFA)对照组.EAMG组大鼠分别于足垫、腹部及背部皮下多点注射丁氏双鳍电鳐的电器官乙酰胆碱受体(AChR)蛋白乳剂共1 ml,第4周再次注射上述乳剂;CFA对照组在相应时间、用相同的方法注射等量CFA;初次注射7周后,分离各组大鼠脾脏T淋巴细胞,体外培养48 h后取上清液分别应用酶联免疫吸附试验和Griess试剂法,检测IFN-γ和NO水平.结果 IFN-γ含量EAMG组为(81.68±10.23)pg/ml,正常对照组为(29.20±5.41)pg/ml,CFA对照组为(31.54±6.12)pg/ml;NO含量EAMG组为(23.68±7.13)μmol/L,正常对照组为(9.05±2.11)μmol/L,CFA对照组为(10.21±2.67)μmol/L;EAMG组IFN-γ和NO水平显著高于正常对照组和CFA对照组(均P＜0.01);正常对照组和CFA对照组间差异无统计学意义.结论 EAMG大鼠T淋巴细胞IFN-γ和NO分泌明显提高;T淋巴细胞IFN-γ-iNOS-NO通路异常可能与MG发病有关.     

Leptin enhances the release of cytokines by peripheral blood mononuclear cells from acute multiple sclerosis patients

Objective To explore the effect of leptin on cytokine production by PBMCs obtained from MS patients either in acute （relapse） or in stable （nonrelapse） phase of disease. Methods PBMCs were collected from 25 untreated acute MS patients, 11 stable MS patients and 20 healthy controls. PBMCs were cultured either with RPMI-1640 alone or with leptin （ 1.25 nmol/ml）, phytohemagglutinin （PHA） （ 100 μg/ml）, and leptin ＋ PHA. 72 h later the supemate of the culture medium were collected and stored at -70℃. The pro-inflammatory cytokine （IFN-γ） concentration were determined using an enzyme-linked immunosorbent assay （ELISA）, and the anti-inflammatory cytokine （IL-4） concentration were investigated by radioimmunity methods. Results Our data showed that leptin induced IFN-γ production by PBMCs of patients in an acute phase of disease but not in a stable phase or in healthy controls. Moreover, we found that PHA induced IL-4 production by PBMCs of patients in an acute phase of disease, but leptin inhibited this ability of PHA. Conelusion Leptin can affect on pro- and anti-inflammatory cytokine production by PBMCs collected from MS patients, may be this connected with leptln increase the susceptiveness of MS.     

AM1241预处理对脂多糖所致小胶质细胞活化及损伤的影响

目的 探讨大麻素CB2受体激动剂AM1241预处理对联用脂多糖(LPS)和γ-干扰素(IFN-γ)所致小胶质细胞活化和损伤的影响.方法 选择小鼠小胶质细胞进行实验,细胞分为对照组、AM1241组、LPS/IFN-γ组和AM1241+LPS/IFN-γ组.对照组细胞正常培养;AM1241组细胞经AM1241预处理2 h后正常培养;LPS/IFN-γ组细胞用含1 μg/mL LPS和50 U/mL,IFN-γ的培养基培养24 h;AM1241+LPS/IFN-γ组细胞经AM1241预处理2 h后,更换正常培养基培养2 h,最后用含1 μg/mL LPS和50 U/mL IFN-γ的培养基培养24 h.采用MTT法检测细胞代谢率,NO检测试剂盒检测细胞培养液中NO释放量,倒置相差显微镜观察细胞形态.结果 AM1241+LPS/IFN-γ组细胞代谢率为92.55%±8.37%,明显高于LPS/IFN-γ组(75.04%±3.01%),差异有统计学意义(P<0.05).AM1241+LPS/IFN-γ组细胞培养基中NO浓度为(43.44±5.52) μmol/L,明显低于LPS/IFN-γ组[(90.87±4.28)μmol/L],差异有统计学意义(P<0.05).LPS/IFN-γ组大量细胞结构被破坏,胞体增大,伪足增粗、变短或消失;AM1241+LPS/IFN-γ组少量细胞结构被破坏,胞体稍增大,伪足较明显.结论 大麻素CB2受体激动剂AM1241预处理可减轻联用LPS和IFN-γ所致的小胶质细胞活化和损伤.

Abstract：

Objective To investigate the effect of preconditioning with cannabinoid CB2 receptor agonist AM1241 on microglial activation and injury induced by lipopolysaccharide ( LPS) and interferon-γ (IFN-γ). Methods The microglial cells were chosen and assigned to control group,AM1241 treatment group, LPS/IFN-γ inducement group and AM1241+LPS/IFN-γ treatment group. Cells of control group were cultured in normal medium;cells of AM1241 treatment group were preconditioned with AM 1241 for 2 h, and then the medium was changed with normal medium;cells of LPS/IFN-γ inducement group were exposed to the medium containing 1 μg/mL LPS plus 50 U/mL IFN-γ for 24 h;cells of AM1241+LPS/IFN-γ treatment group were preconditioned with AM1241, then the medium were changed with normal medium for 2 h, and at last, cells of this group were exposed to 1 μg/mL LPS plus 50 U/mL IFN-γ for 24 h. Microglial metabolism was assessed by MTT assay;NO release was measured by Reagent Kit;microglial shapes were observed through microscope. Results CB2 receptor agonist preconditioning can up-regulate the microglial CB2 receptor expression markedly;cell metabolism of AM1241+LPS/IFN-γ treatment group (92.55 ±8.37%) was obviously higher than that of LPS/IFN-γ inducement group (75.04±3.01%, P<0.05);AM1241+LPS/IFN-γ treatment group (43.44±5.52 μmol/L) released significantly less NO than LPS/IFN-γ inducement group (90.87±4.28 (μmol/L, P<0.05). Cells of the LPS/IFN-γ inducement group were destroyed seriously with enlarged soma and thickened and shortened pseudopodium;cells of the AM1241+LPS/IFN-γ treatment group were destroyed slightly with slightly enlarged soma and thickened and shortened pseudopodium. Conclusion Preconditioning with cannabinoid CB2 receptor agonist AM1241 reduces microglial activation and injury induced by LPS plus IFN-γ.     

Th1/Th2型细胞因子在实验性自身免疫性神经炎发病机制中的作用

目的 建立P2多肽诱导的实验性自身免疫性神经炎(EAN)大鼠模型,探讨Th1/Th2型细胞因子在EAN发病机制中的作用.方法 实验组用100 μg或200 μg P257-81多肽加完全弗氏佐剂(FCA)免疫Lewis大鼠,对照组单用FCA免疫,致敏后每日对大鼠进行临床评分,比较高峰期最高评分.致敏第14天测定淋巴结细胞培养液上清干扰素(IFN)-γ、IL-4及IL-10的含量,并进行坐骨神经病理学检查.结果 实验大鼠瘫痪高峰期最高评分P257-81 200 μg组(3.6±0.3)显著高于100 μg组(2.2±0.6,P＜0.01);P257-81 200 μg组大鼠病程显著长于100 μg组;IFN-γ含量,两组实验大鼠均显著高于对照组[分别为(530.6±91.7)、(806.3±132.4)和(35.0±5.9)pg/ml,均P＜0.01],而P257-81 200 μg组显著高于100 μg组(P＜0.01);IL-4和IL-10含量,P257-81 100 μg组均显著高于对照组(均P＜0.01),P257-81 200 μg组显著低于对照组(P＜0.05,P＜0.01);坐骨神经病理可见EAN急性期以炎性细胞浸润为主,P257-81 200 μg组慢性期无炎性细胞浸润,而表现为多发性局灶性脱髓鞘和神经纤维崩解未恢复.结论 EAN临床表现随致敏原P257-81多肽剂量增加而加重;在EAN急性期,IFN-γ水平与EAN临床表现大致平行;EAN疾病具有自限性可能与IL-4和IL-10水平增高有关,而疾病迁延可能与IL-4和IL-10水平降低有关.     

MBP对PBMC产生IFN-γ和NO的影响

目的探讨T细胞非特异性活化在CNS脱髓鞘性疾病中的作用。方法分离实验性自身免疫性脑脊髓炎(EAE)易感性BALB/c小鼠外周血单个核细胞(PBMC),采用体外细胞培养方法在体外与碱性髓鞘蛋白(MBP)共培养,测定培养上清液中IFN-γ、NO水平。结果经MBP刺激的PBMC产生IFN-γ[(43.83±6.06)pg/mL]和NO[(180.76±20.75)μmol/L]明显增加,与对照组产生的IFN-γ[(28.52±2.18)pg/mL]和NO[(95.61±13.09)μmol/L]相比差异有统计学意义(P<0.01)。结论在CNS脱髓鞘性疾病发病过程中,活化的T细胞、单核细胞等分泌致炎细胞因子和其他有害物质增多。     

钾通道阻滞剂对多发性硬化患者细胞因子分泌的影响

目的研究多发性硬化(multiple sclerosis,MS)患者髓鞘反应性CD4+T淋巴细胞分泌γ干扰素(INF-γ)和白细胞介素-4(IL-4)的水平,并探讨钾通道阻滞剂对其分泌的影响。方法采用酶联免疫斑点方法(ELISPOT)对12例急性期MS患者、12例缓解期MS患者(经INF--β1b治疗)和10名健康对照的CD4+T淋巴细胞在有无髓鞘抗原和钾通道阻滞剂作用下分泌细胞因子INF-γ和IL-4的变化进行比较。结果 MS急性期外周血CD4+T细胞以分泌IFN-γ为主;MS急性期及缓解期的CD4+T淋巴细胞经髓鞘碱性蛋白(MBP)刺激后分泌IFN-γ的水平较未加抗原组均增高(P<0.05),加入Kv1.3通道阻滞剂海葵毒素(Stichodactyla helianthustoxin,SHK)后,MS急性期和缓解期的MBP反应CD4+T淋巴细胞IFN-γ分泌明显减低(P<0.05),而对IL-4无明显影响。结论 Kv1.3钾通道阻滞剂SHK能减少MS患者MBP反应CD4+T细胞分泌IFN-γ,提示髓鞘反应性CD4+T细胞上Kv1.3通道有可能作为治疗MS的新靶点。     

IFN-γ和热干预对U251胶质瘤细胞的MHC-I类分子和HSP70表达的影响

目的 观察重组人干扰素-γ(IFN-γ)和热干预对人多形胶质母细胞瘤(GBM)U251细胞胞膜主要组织相容性抗原复合体-I(MHC-I)类分子和热休克蛋白70(HSP70)分子表达的影响.方法 将U251细胞分为3个干预组:IFN干预组(IFN-γ500 U/ml诱导48h),热干预组(43℃热休克2h).联合干预组(IFN-γ500U/ml诱导48h+43℃热休克2h),分别行相应诱导干预.流式细胞仪(FCM)检测不同干预因素处理后的U251细胞胞膜MHC-I类分子和HSP70表达情况.结果 IFN干预组、热干预组、联合干预组U251细胞胞膜MHC-I及HSP70表达率分别为(89.92±3.45)%和(5.11±1.89)%、(78.89±2.02)%和(42.18±3.85)%、(96.00.4±2.63)%和(53.61±4.24)%.结论 双因素(IFN-γ500 U/ml诱导48 h+43℃热休克2 h)联合干预是U251细胞胞膜MHC-I类分子和HSP70双高表达的最佳体外诱导方案.     

抗CD40配体单克隆抗体干预重症肌无力的研究

目的研究抗CD40配体单克隆抗体(CD40LmcAb)干预重症肌无力(MG)患者外周血单个核细胞(PBMC)的效果并探讨其机制。方法MG患者25例和健康对照组16名,分离培养外周血单个核细胞,分别用植物血凝素(PHA)和美洲商陆原(PWM)进行刺激,并用CD40LmcAb进行干预。PHA刺激组培养后收集上清检测γ干扰素(IFN γ)和白细胞介素4 (IL 4);PWM刺激组培养后收集上清检测抗乙酰胆碱受体抗体(AchRab)和抗突触前膜受体抗体(PsmRab)。比较MG患者两组中CD40LmcAb干预与否的差异并与健康对照组比较。结果MG患者PBMC体外诱生AchRab(0 32±0 11)、PsmRab(0 28±0 11)、IFN γ[ (36 24±10 47)pg/ml]和IL 4水平[ (263 08±35 95)pg/ml]对比健康对照组显著增高[分别为(0 10±0 02), (0 15±0 03), (17 56±2 94)pg/ml和(190 00±6 50)pg/ml,P<0 01),CD40LmcAb干预后MG组的上述四项指标均基本降至健康对照组水平(P>0 05)。结论CD40LmcAb在体外能有效干预MG患者PBMC诱生AchRab、PsmRab、IFN γ和IL 4的水平。     

Guillain-Barre综合征患者B淋巴细胞辅助受体CD22、CD72表达的研究

目的探讨Gu illain-Barre综合征(GBS)患者外周血B淋巴细胞辅助受体CD22、CD72表达及其与GBS病程和病情的关系。方法 36例GBS患者(GBS组)按病程及病情分为急性期亚组与恢复期亚组和轻症亚组与重症亚组,应用流式细胞术检测外周血B淋巴细胞CD22及CD72蛋白表达,比较CD22与CD72蛋白在不同亚组间的表达;并与正常对照组(20人)比较。结果 B细胞数量GBS组[(606±118)个]较正常对照组[(248±92)个]明显升高,CD72+CD19+阳性细胞率[(62.11±9.14)%]较正常对照组[(69.72±11.42)%]明显降低(均P<0.01);CD22+CD19+阳性细胞率两组间差异无统计学意义。GBS组中,急性期亚组[(682±91)个]B细胞数量较恢复期亚组[(550±111)个]明显升高,CD72+CD19+阳性细胞率急性期亚组[(57.79±7.69)%]较恢复期亚组[(68.14±7.58)%]明显降低(均P<0.01);CD22+CD19+阳性细胞率两亚组间差异无统计学意义;重症亚组[(685±116)个]较轻症亚组B细胞数量[(561±96)个]明显升高(...     

拉莫三嗪诱发皮肤不良反应与TCRBV基因表达的相关性研究

目的研究拉莫三嗪(LTG)激活T细胞介导免疫应答而诱发皮肤不良反应(cADRs)的可能致病机制;通过分析在LTG诱发的cADRs(LTG-cADRs)患者与LTG耐受者外周血单个核细胞(PBMCs)中TCRBV基因表达的差异,探讨LTG-cADRs与T细胞受体β家族V基因(TCRBV基因)表达的相关性。方法收集10例cADRs已治愈达6周以上的LTG-cADRs患者(病例组),依据病例对照研究的方法按1︰1匹配纳入10例LTG耐受者(对照组),分离病例组与对照组患者PBMCs,给予LTG体外刺激并培养,采用ELISA法测定病例组与对照组患者PBMCs分泌干扰素γ(IFN-γ)、白细胞介素5(IL-5)及肿瘤坏死因子β(TNF-β)的情况,运用实时荧光定量逆转录PCR技术(RT-qPCR)的SYBR GreenⅠ荧光染料法检测TCRBV基因的表达,比较两组IFN-γ、IL-5及TNF-β水平及TCRBV基因相对表达量的差异。结果病例组细胞上清液中IFN-γ水平明显高于对照组[分别为(1.06±0.09)ng/mL、(0.86±0.16)ng/mL,P0.05]。病例组细胞上清液中IL-5和TNF-β水平与对照组差异无统计学意义(均P0.05)。病例组TCRBV11、TCRBV15、TCRBV17、TCRBV18、TCRBV19基因的相对表达量[中位数(四分位数间距)]分别为1.78(1.07)、1.83(2.19)、2.13(3.39)、1.79(1.92)、1.44(1.62),均高于对照组[分别为1.00(0.43)、1.08(1.13)、1.05(0.71)、0.96(0.72)、1.01(0.61),均P0.05]。结论 LTG可在体外激活LTG-cADRs患者的PBMCs分泌IFN-γ,提示T细胞介导的免疫反应可能参与了LTG-cADRs的致病机制。LTG-cADRs可能与TCRBV11、TCRBV15、TCRBV17、TCRBV18、TCRBV19基因的表达相关。     

白介素-1β基因多态性及核因子-kB对精神分裂症首次发病患者血清白介素-1β水平的影响

目的 探讨精神分裂症患者白介素-1β(IL-1β)基因多态性及核因子-kB(NF-kB)对IL-1β水平的影响.方法 采用聚合酶链反应-限制性内切酶方法检测161例精神分裂症患者(患者组)和135名正常对照者(对照组)的IL-1β基因-511多态性位点和+3953多态性位点的基因型及等位基因频率;采用酶联免疫吸附法检测IL-1β在患者组和对照组血清中的蛋白表达及外周血单个核细胞( PBMC) NF-kB活性;采用逆转录-聚合酶链反应方法检测PBMC IL-1β mRNA表达水平.结果 (1) IL-1β -511G/A位点的等位基因G与精神分裂症存在名义上的关联(P=0.038,多重检验P =0.240),但+3953G/A多态性与精神分裂症无关联(P＞0.05).(2)患者组血清IL-1β水平[(25.93±13.30) ng/L]、PBMC中IL-1β mRNA( 1.30±0.30)表达以及NF-kB活性[(0.28±0.21) μg/L]均高于对照组[(14.19±7.86) ng/L、0.97±0.27、(0.20±0.17) μg/L;P均＜0.05];携带IL-1β基因-511A/G和+3953A/G位点基因型GA和AA的精神分裂症患者较GG携带者的IL-1β水平明显增高(P＜0.05).结论 精神分裂症患者外周血IL-1β水平的增高参与了疾病的病理生理过程,基因多态性和转录因子NF-kB均对细胞因子的分泌起了一定作用.     

地塞米松对MS的IFN-γ-10分泌性T细胞的影响

目的检测多发性硬化(MS)患者外周血单个核细胞在地塞米松(Dex)影响下的IFN-γ和IL-10的分泌细胞水平.方法采用酶联免疫斑点技术(ELISPOT)检测体外培养的外周血单个核细胞(MNC)在CNS髓鞘素抗原MBP刺激下的地塞米松对照试验,检测IFN-γ和IL-10分泌性T细胞水平,并与其他神经疾病(OND)组及健康对照组的检测结果进行对比.结果显示MS患者IFN-γ分泌细胞水平高于对照组,Dex使MS患者IFN-γ分泌细胞减少,对IL-10分泌细胞无明显影响.结论MS患者存在Th1/Th2细胞因子的失衡,Dex能抑制MSTh1类细胞因子IFN-γ,其治疗作用可能与此有关.     

丙种球蛋白对格林-巴利综合征患者白介素12与白介素18表达的影响及其相关性研究

目的探讨丙种球蛋白治疗对格林-巴利综合征(GBS)对患者体内白介素12(IL12)和白介素18(IL18)的表达的影响。方法用ELISA方法对静脉注射丙种球蛋白(IVIG)治疗GBS前后的血清、脑脊液IL12和IL18表达,同时用RT-RCR法检测血淋巴细胞白介素12受体(IL12R)mRNA与IL18RmRNA的表达。结果17例GBS治疗前血清IL12含量为45.6±12.2pg/ml,治疗后为17.1±4.74pg/ml(P<0.01);IL18治疗前为157.5±39.3pg/ml,治疗后为126.2±22.6pg/ml。5例GBS治疗前脑脊液IL12为25.2±5.8pg/ml,治疗后为16.7±3.6pg/ml。IL-18治疗前为121.8±27.9pg/ml,治疗后为53.6±15.6pg/ml。17例GBS治疗前血淋巴细胞表面受体IL-12RmRNA的表达强度为0.2948±0.098,治疗后为0.1507±0.087,与治疗前比显著降低(P<0.05)。治疗前血淋巴细胞IL18RmRNA表达强度为0.5352±0.1134,治疗后为0.2843±0.1127,与治疗前比显著降低(P<0.05)。IL12与IL18蛋白在血清中的表达呈显著正相关;IL12与IL18淋巴细胞表面受体mRNA的表达呈显著正相关。结论丙种球蛋白治疗能够下调GBS患者IL12与IL18的表达。